Lanean...
TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy
BACKGROUND: Immunotherapies have revolutionized cancer treatment. Unlike chemotherapies, immune agents often take longer to show benefit, and the complex and unique mechanism of action of these agents renders the use of multiple endpoints more appropriate in some trials. These new features of immuno...
Gorde:
| Argitaratua izan da: | J Natl Cancer Inst |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8204709/ https://ncbi.nlm.nih.gov/pubmed/30924863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djz049 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|